Twist Bioscience Corp (NASDAQ:TWST)’s traded shares stood at 1.18 million during the last session, with the company’s beta value hitting 2.54. At the close of trading, the stock’s price was $37.71, to imply a decrease of -1.59% or -$0.61 in intraday trading. The TWST share’s 52-week high remains $60.90, putting it -61.5% down since that peak but still an impressive 19.6% since price per share fell to its 52-week low of $30.32. The company has a valuation of $2.25B, with an average of 0.93 million shares in intraday trading volume over the past 10 days and average of 1.17 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Twist Bioscience Corp (TWST), translating to a mean rating of 1.77. Of 7 analyst(s) looking at the stock, 0 analyst(s) give TWST a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.56.
Twist Bioscience Corp (NASDAQ:TWST) trade information
After registering a -1.59% downside in the last session, Twist Bioscience Corp (TWST) has traded red over the past five days. The 5-day price performance for the stock is -6.12%, and -3.16% over 30 days. With these gigs, the year-to-date price performance is -18.85%. Short interest in Twist Bioscience Corp (NASDAQ:TWST) saw shorts transact 9.73 million shares and set a 7.71 days time to cover.
The extremes give us $50 and $58 for target low and target high price respectively. As such, TWST has been trading -53.81% off suggested target high and -32.59% from its likely low.
Twist Bioscience Corp (TWST) estimates and forecasts
The rating firms project that company’s revenue will grow 19.92% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is 92.04M. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 95.26M.Earnings reports from the last fiscal year show that sales brought in 75.3M and 81.46M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 22.22% before jumping 16.94% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 1.70% for the past 5-year period. While 2025 is set for a 43.36% return in earnings, projections for the next 5 years are at 37.54% annually.
TWST Dividends
Twist Bioscience Corp has its next earnings report out on 2025-Feb-02. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Twist Bioscience Corp (NASDAQ:TWST)’s Major holders
Twist Bioscience Corp insiders hold 2.08% of total outstanding shares, with institutional holders owning 111.27% of the shares at 113.63% float percentage. In total, 111.27% institutions holds shares in the company, led by ARK INVESTMENT MANAGEMENT LLC. As of 2024-06-30, the company held over 6.13 million shares (or 10.5415% of shares), all amounting to roughly $302.06 million.
The next major institution holding the largest number of shares is ARTISAN PARTNERS LIMITED PARTNERSHIP with 6.07 million shares, or about 10.4371% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $299.06 million.
We also have ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF as the top two Mutual Funds with the largest holdings of the Twist Bioscience Corp (TWST) shares. Going by data provided on Mar 31, 2025 , ARK ETF Trust-ARK Innovation ETF holds roughly 3.54 shares. This is just over 5.93% of the total shares, with a market valuation of $133.4 million. Data from the same date shows that the other fund manager holds a little less at 2.26, or 3.78% of the shares, all valued at about 85.1 million.
